Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Not Yet Opened 11-05 16:00:00 EST

1.40

-0.02

-1.76%

盘后1.40

+0.000.00%

19:05 EST

High1.59	Low1.34	Vol51.30K
Open1.50	D1 Closing1.42	Amplitude17.61%
Mkt Cap2.63M	Tradable Cap1.80M	Total Shares1.89M
T/O74.53K	T/O Rate3.97%	Tradable Shares1.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":1.395,"timestamp":1793912400000,"preClose":1.42,"halted":0,"volume":51301,"hourTrading":{"tag":"盘后","latestPrice":1.395,"preClose":1.395,"latestTime":"19:05 EST","volume":20,"amount":28.375,"timestamp":1793923532236,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01760563380281684,"floatShares":1292320,"shares":1888305,"eps":-8.73186,"marketStatus":"Not Yet Opened","change":-0.025,"latestTime":"11-05 16:00:00 EST","open":1.5,"high":1.59,"low":1.34,"amount":74533,"amplitude":0.176056,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.73186,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793955600000},"marketStatusCode":0,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":1.42,"preHourTrading":{"tag":"盘前","latestPrice":1.48,"preClose":1.42,"latestTime":"09:28 EST","volume":154,"amount":224.9200184,"timestamp":1793888884112,"change":0.06,"changeRate":0.042254,"amplitude":0.021127},"postHourTrading":{"tag":"盘后","latestPrice":1.395,"preClose":1.395,"latestTime":"19:05 EST","volume":20,"amount":28.375,"timestamp":1793923532236,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.515267},"requestUrl":"/m/hq/s/NRSN","defaultTab":"news","newsList":[{"id":"2680971956","title":"Neurosense Therapeutics Ltd : H.c. Wainwright Cuts to Neutral from Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2680971956","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680971956?lang=en_us&edition=fundamental","pubTime":"2026-11-03 12:57","pubTimestamp":1793681870,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nFWN46K096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680527760","title":"Neurosense Shares Fall After HC Wainwright Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2680527760","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680527760?lang=en_us&edition=fundamental","pubTime":"2026-11-03 04:01","pubTimestamp":1793649696,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics (NRSN) shares were down almost 30% in Monday trading after HC Wainwright downgraded the stock to neutral from buy.Intraday trading volume was more than 400,000 shares, against a daily average of roughly 23,000 shares.Price: 1.40, Change: -0.59, Percent Change: -29.65","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680761169","title":"NeuroSense downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2680761169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680761169?lang=en_us&edition=fundamental","pubTime":"2026-11-03 00:45","pubTimestamp":1793637933,"startTime":"0","endTime":"0","summary":"H.C. Wainwright downgraded NeuroSense (NRSN) to Neutral from Buy. Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680768045","title":"Neurosense to Strengthen Primec Canadian ALS Submission with New Nfl Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2680768045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680768045?lang=en_us&edition=fundamental","pubTime":"2026-11-02 22:04","pubTimestamp":1793628283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nFWN46J2P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680768003","title":"Neurosense Therapeutics - Advancing Discussions with Commercialization Partners for Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2680768003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680768003?lang=en_us&edition=fundamental","pubTime":"2026-11-02 22:04","pubTimestamp":1793628283,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nFWN46J2P9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSNW","BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680680257","title":"NeuroSense Adds New ALS Biomarker Data to Planned Canadian PrimeC Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2680680257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680680257?lang=en_us&edition=fundamental","pubTime":"2026-11-02 22:04","pubTimestamp":1793628275,"startTime":"0","endTime":"0","summary":"NeuroSense adds new ALS biomarker data to planned Canadian PrimeC submissionNeuroSense Therapeutics moved its Canadian PrimeC filing target to March 2027 from December 2026 to include new ALS trial da","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL6Lky8k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679828178","title":"NeuroSense Presents PrimeC Clinical and Biomarker Findings at NEALS Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2679828178","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679828178?lang=en_us&edition=fundamental","pubTime":"2026-10-29 23:31","pubTimestamp":1793287865,"startTime":"0","endTime":"0","summary":"NeuroSense Presents PrimeC Clinical and Biomarker Findings at NEALS Annual MeetingNeuroSense Therapeutics will present at the NEALS Consortium annual meeting on Oct. 30, 2026, in Clearwater, Florida.S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL6T3Cr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678905461","title":"Neurosense Therapeutics Ltd: Targets First Primec Revenues in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2678905461","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678905461?lang=en_us&edition=fundamental","pubTime":"2026-10-27 00:48","pubTimestamp":1793033307,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nFWN46C1AD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678819054","title":"Neurosense Therapeutics Ltd: Signs Strategic Collaboration Agreement to Advance Primec Supply for ALS Patients - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2678819054","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678819054?lang=en_us&edition=fundamental","pubTime":"2026-10-27 00:48","pubTimestamp":1793033307,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261026:nFWN46C1AD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676686378","title":"NeuroSense files patent in USPTO covering methods to treat TBI","url":"https://stock-news.laohu8.com/highlight/detail?id=2676686378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676686378?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:37","pubTimestamp":1792413441,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that it has filed a patent application with the U.S. Patent and Trademark Office covering methods of treat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-files-patent-in-uspto-covering-methods-to-treat-tbi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-files-patent-in-uspto-covering-methods-to-treat-tbi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139","USRD","TBI","BK4130"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676854486","title":"Neurosense Therapeutics Ltd: if Granted, Patent is Expected to Provide Protection Through 2047, Subject to Any Extensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2676854486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676854486?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:25","pubTimestamp":1792412725,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nFWN4650Y0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676685490","title":"Neurosense Files U.S. Patent Application for Traumatic Brain Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2676685490","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676685490?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:25","pubTimestamp":1792412725,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nFWN4650Y0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675354922","title":"NeuroSense Sets Nov. 10 NASDAQ Panel Hearing After Delisting Notice over Market Value Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2675354922","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675354922?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:31","pubTimestamp":1791894686,"startTime":"0","endTime":"0","summary":"NeuroSense sets Nov. 10 Nasdaq panel hearing after delisting notice over market value ruleNeuroSense won a Nasdaq hearing on Nov. 10, 2026, challenging an Oct. 1 staff delisting determination.Trading ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL5Yf69y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675780013","title":"NeuroSense downgraded to Neutral from Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2675780013","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675780013?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:35","pubTimestamp":1791837318,"startTime":"0","endTime":"0","summary":"Roth Capital downgraded NeuroSense (NRSN) to Neutral from Buy with a $3.50 price target The firm cites the company’s PrimeC Phase 3 study delay for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-downgraded-to-neutral-from-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672074918","title":"Neurosense Therapeutics Receives Nasdaq Listing Compliance Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2672074918","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672074918?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:36","pubTimestamp":1790973414,"startTime":"0","endTime":"0","summary":"Neurosense Therapeutics (NRSN) said late Friday it received a letter from the Nasdaq Listing Qualifications Department on Thursday stating that it has not regained compliance with the Nasdaq listing r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","LCLG","NRSN","NQmain","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749875","title":"NeuroSense Faces NASDAQ Delisting Risk After Missing $35 Million Market Value Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749875","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749875?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:15","pubTimestamp":1790972125,"startTime":"0","endTime":"0","summary":"NeuroSense faces Nasdaq delisting risk after missing $35 million market value ruleNeuroSense received a Nasdaq staff delisting determination for failing to meet the $35 million minimum market value of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL44QtMd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749848","title":"Neurosense Provides Update on NASDAQ Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749848?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:15","pubTimestamp":1790972100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nTUA4F1SJK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN","NRSNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671200378","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:46 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2671200378","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671200378?lang=en_us&edition=fundamental","pubTime":"2026-09-30 21:46","pubTimestamp":1790776005,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:46 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nAQN2MLGW6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671251681","title":"NeuroSense CFO Eisenberg Joins ROTH Healthcare Opportunities Conference Investor Meetings","url":"https://stock-news.laohu8.com/highlight/detail?id=2671251681","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671251681?lang=en_us&edition=fundamental","pubTime":"2026-09-29 00:43","pubTimestamp":1790613823,"startTime":"0","endTime":"0","summary":"NeuroSense CFO Eisenberg joins ROTH Healthcare Opportunities Conference investor meetingsNeuroSense to attend the 5th Annual ROTH Healthcare Opportunities Conference on Sept. 29, 2026, in New York Cit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL7YdlwW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670239370","title":"NeuroSense target adjusted to $52 from $8 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239370","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670239370?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:20","pubTimestamp":1790590825,"startTime":"0","endTime":"0","summary":"H.C. Wainwright adjusted the firm’s price target on NeuroSense (NRSN) to $52 from $8 and keeps a Buy rating on the shares following the 1:20 revers...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-target-adjusted-to-52-from-8-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-target-adjusted-to-52-from-8-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":-0.3451},{"period":"1month","weight":-0.6572},{"period":"3month","weight":-0.8605},{"period":"6month","weight":-0.9207},{"period":"1year","weight":-0.9335},{"period":"ytd","weight":-0.9093}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.184296},{"month":3,"riseRate":0.4,"avgChangeRate":0.030043},{"month":4,"riseRate":0.6,"avgChangeRate":-0.103871},{"month":5,"riseRate":0.4,"avgChangeRate":-0.003304},{"month":6,"riseRate":0.6,"avgChangeRate":0.298631},{"month":7,"riseRate":0,"avgChangeRate":-0.259476},{"month":8,"riseRate":0.4,"avgChangeRate":-0.11133},{"month":9,"riseRate":0.4,"avgChangeRate":-0.040284},{"month":10,"riseRate":0,"avgChangeRate":-0.22559},{"month":11,"riseRate":0.6,"avgChangeRate":0.284656},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}